Back to results
US 11,590,329 B2Granted
Allergic rhinitis drug delivery implant
AssigneeSpirox, Inc.
InventorsGene Michal, Daniel L. Cox, Piyush Arora, Michael S. Mirizzi, Scott Baron
Life of this patent
Estimating the term…
Abstract
In another example, a bioresorbable implant for use in a nasal region includes one or more bioresorbable polymers, and a pharmaceutical composition coupled to the one or more bioresorbable polymers. A release rate of the pharmaceutical composition is related to a degradation rate of the one or more bioresorbable polymers.
Claims19
A method of treating tissue in a nasal cavity, comprising:
- inserting a bioresorbable implant into a soft tissue of the nasal cavity, wherein the bioresorbable implant comprises:
- a porous bioresorbable tube defined by a wall formed from one or more porous bioresorbable polymers, the porous bioresorbable tube including pores and an interior bore that extends from a first end to a second end, and
- a pharmaceutical composition loaded in the wall of the porous bioresorbable tube and filling at least partially the interior bore of the porous bioresorbable tube;
- and
- after inserting the bioresorbable implant into the soft tissue of the nasal cavity, releasing the pharmaceutical composition from the bioresorbable implant,
- wherein the wall of the porous bioresorbable tube is configured to control a release rate of the pharmaceutical composition over time, the release rate is determined by:
- (i) a release of the pharmaceutical composition loaded in the wall of the porous bioresorbable tube, wherein the release of the pharmaceutical composition loaded in the wall leaves channels in the wall, and
- (ii) a release of the pharmaceutical composition from the interior bore:
- (a) via a degradation of the one or more porous bioresorbable polymers,
- (b) through the pores of the porous bioresorbable tube, and
- (c) through the channels left by the release of the pharmaceutical composition loaded in the wall of the porous bioresorbable tube, wherein the release of the pharmaceutical composition from the interior bore occurs more quickly as the pharmaceutical composition loaded in the wall of the porous bioresorbable tube is released.
8 more elements
A bioresorbable implant for use in a nasal region, comprising:
- a porous bioresorbable tube defined by a wall formed from one or more porous bioresorbable polymers, the porous bioresorbable tube including pores and an interior bore that extends from a first end to a second end;
- and
- a pharmaceutical composition loaded in the wall of the porous bioresorbable tube and filling at least partially the interior bore of the porous bioresorbable tube,
- wherein a release rate of the pharmaceutical composition from the bioresorbable implant is determined by:
- (i) a release of the pharmaceutical composition loaded in the wall of the porous bioresorbable tube, wherein the release of the pharmaceutical composition loaded in the wall leaves channels in the wall, and
- (ii) a release of the pharmaceutical composition from the interior bore:
- (a) via a degradation of the one or more porous bioresorbable polymers,
- (b) through the pores of the porous bioresorbable tube, and
- (c) through the channels left by the release of the pharmaceutical composition loaded in the wall of the porous bioresorbable tube, wherein the release of the pharmaceutical composition from the interior bore occurs more quickly as the pharmaceutical composition loaded in the wall of the porous bioresorbable tube is released.
6 more elements
A system, comprising:
- a bioresorbable implant comprising:
- a porous bioresorbable tube defined by a wall formed from one or more porous bioresorbable polymers, the porous bioresorbable tube including pores and an interior bore that extends from a first end to a second end;
- and
- a pharmaceutical composition loaded in the wall of the porous bioresorbable tube and filling at least partially the interior bore of the porous bioresorbable tube,
- wherein a release rate of the pharmaceutical composition from the porous bioresorbable tube is determined by:
- (i) a release of the pharmaceutical composition loaded in the wall of the porous bioresorbable tube, wherein the release of the pharmaceutical composition loaded in the wall leaves channels in the wall, and
- (ii) a release of the pharmaceutical composition from the interior bore:
- (a) via a degradation of the one or more porous bioresorbable polymers,
- (b) through the pores of the porous bioresorbable tube, and
- (c) through the channels left by the release of the pharmaceutical composition loaded in the wall of the porous bioresorbable tube, wherein the release of the pharmaceutical composition from the interior bore occurs more quickly as the pharmaceutical composition loaded in the wall of the porous bioresorbable tube is released;
- and
- a delivery device configured to insert the bioresorbable implant in a soft tissue of a nasal cavity.
9 more elements
Dependencies are inferred from the claim text.